Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Treatment Trial in Acute Coronary Syndrome
2025-522136-14-00Phase 4Authorised
- Sponsor
- Tays Sydänkeskus
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ceftriaxone and amoxicillin in myocardial infarction (MI), Non-ST-segment elevation myocardial infarction (NSTEMI) and coronary arteriosclerosis, sponsored by Tays Sydänkeskus. Primary endpoint: Major adverse cardiac and cerebrovascular events (MACCE) at 12 months. Planned start Aug 2025; status: authorised.
02
Drugs
ceftriaxoneamoxicillin
03
Conditions
myocardial infarction (MI)Non-ST-segment elevation myocardial infarction (NSTEMI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-522136-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522136-14-00.